By Tyler Stahl, M.S., Nerac Analyst
Originally published April 27, 2017
This article explores recent trends in the developing field of tissue engineering and regenerative medicine.
Read More
Regenerative Medicine: A New Kind of Cellular Service
Exciting Novel, but High-Cost Developments in Cancer Treatment: Immunotherapy continues to advance as a validated approach
By Holly Magna, Ph.D., Nerac Analyst
Originally published November 28, 2016
A review of some of the newly marketed therapies and some still in development, as well as their complications, risks and advantages
Read More
Drug Safety Updates – Regulations and FDA Guidance for Industry
By Stephen Buxser, Ph.D., Nerac Analyst
Originally published November 28, 2016
For drugs licensed for sale in the United States, as well as elsewhere in the world, there are requirements for periodic literature updates/reviews. This article describes the legal requirements for drug safety and efficacy reporting.
Read More
Antibiotic Resistant Bacteria – Threats and Opportunities.
By Stephen E. Buxser, Ph.D., Nerac Analyst,
Originally Published: November 6, 2015
This report looks into the issue of antibiotic resistance and the development of new antimocrobials. Read More
The Fight Over Who Invented siRNA
By John Leavitt, Ph.D., Nerac Analyst
Originally Published: June 1st, 2015
The Tuschl II priority application describing the invention of siRNA for therapeutic gene silencing assigned to Max-Planck Institute was filed in the European Patent Office to establish a priority date of the December 1, 2000.
Read More
Epithelial to Mesenchymal Transition in Lethal Forms of Cancer and Fibrotic Disease
By John Leavitt, Ph.D., Nerac Analyst,
Originally Published: February 17th, 2015
This article describes very recent developments cancer genetics and cell biology that helps to understand the importance of EMT in cancer and fibrosis mortality. Read More
Ebola: Do we need to worry?
By Rebecca Ryznar, Ph.D., Nerac Associate Analyst
Originally published Sept. 2, 2014
Zaire Ebola virus (EBOV), the particular Ebola viral strain currently spreading across West Africa, causes the most virulent hemorrhagic fever known to man, and kills up to 90% of those infected. Read more
A Glimpse into the Vital Core of Tumor Cell Development
By John Leavitt, Ph.D. Nerac Analyst
Originally Published: August 12, 2014
In 1987, my colleagues at Stanford and I published a paper that clearly demonstrated that expression of a charge-altered mutant human beta-actin (glycine to aspartic acid substitution at amino acid 245; G245D) caused non-tumorigenic, immortalized human fibroblasts to form aggressive tumors in nude mice (Leavitt et al, 1987a). Read more
Nutraceutical IP and Regulatory Claims
Originally published September, 2008
Food makers increasingly rely on patented technologies to improve functionality, but strict regulations hamper marketing benefits.
Read more
When Did Proteomics Begin?
By John Leavitt, Ph.D. Nerac Analyst
Originally Published: July 21, 2014
Over the past two decades I have been somewhat amused by the seemingly abrupt emergence of the fields called “genomics” and “proteomics” and all of the other “…omics”. Read more